Login to Your Account



Washington Roundup

Congress Hears Opposing Views in Follow-on Biologics Debate

By Donna Young


Monday, June 23, 2008
WASHINGTON - Firms seeking to gain approval of follow-on biologics (FOBs) should be required by law to conduct clinical trials to demonstrate the products' safety and effectiveness, the Pharmaceutical Research and Manufacturers of American (PhRMA) told a congressional subcommittee. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription